Technical analysis outlines how multi-agent architecture enhances drug discovery workflows, suggesting improved automation outcomes.
Building on the conceptual framework presented in our previous work on agentic AI for pharmaceutical research, this paper provides a comprehensive technical analysis of Tippy's multi-agent system implementation for drug discovery laboratory automation. We present a distributed microservices architecture featuring five specialized agents (Supervisor, Molecule, Lab, Analysis, and Report) that coordinate through OpenAI Agents SDK orchestration and access laboratory tools via the Model Context Protocol (MCP). The system architecture encompasses agent-specific tool integration, asynchronous communication patterns, and comprehensive configuration management through Git-based tracking. Our production deployment strategy utilizes Kubernetes container orchestration with Helm charts, Docker containerization, and CI/CD pipelines for automated testing and deployment. The implementation integrates vector databases for RAG functionality and employs an Envoy reverse proxy for secure external access. This work demonstrates how specialized AI agents can effectively coordinate complex laboratory workflows while maintaining security, scalability, reliability, and integration with existing laboratory infrastructure through standardized protocols.
No takes yet. Share an insight, caveat, or question.
Fehlis et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: